Breakthrough Rapid-Acting Treatment Shows Promise for Platelet Disorder Patients in Phase 2 Trial
In a groundbreaking development for the treatment of immune thrombocytopenia (ITP), a recent phase 2 clinical trial has demonstrated that the investigational antibody mezagitamab significantly...















